

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
**WO 03/061766 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 17/08**,  
17/10, A61K 31/23, 31/225, 7/48

(21) International Application Number: PCT/IT02/00791

(22) International Filing Date:  
13 December 2002 (13.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
BS2001A000111  
20 December 2001 (20.12.2001) IT

(71) Applicant: **GENERAL TOPICS S.R.L.** [IT/IT]; Via  
Lungolago Zanardelli 32, I-25087 Salo (Brescia) (IT).

(72) Inventor: **DE PAOLI AMBROSI, Gianfranco**; Via Cure  
del lino 32, 25087 Salo (Brescia) (IT).

(74) Agent: **SANGIACOMO, Fulvia**; Biesse S.R.L., Corso  
Matteotti, 42, I-25122 Brescia (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION BASED ON ETYLLINOLEATE AND TRIETHYLCITRATE FOR THE TREATMENT OF SEBORRHEA AND ACNE

(57) Abstract: The present invention relates to a composition for topical use for treating and improving the aesthetic conditions of the skin, which comprises, as an active ingredient, a mixture of ethyllinoleate and triethylcitrate. This composition is active in the treatment of seborrhea and acne.



**WO 03/061766 A1**

"COMPOSITION BASED ON ETYLLINOLEATE AND TRIETHYLCITRATE  
FOR THE TREATMENT OF SEBORRHEA AND ACNE"

\* \* \* \* \*

## FIELD OF INVENTION

This invention concerns a new product for pharmaceutical and/or cosmetic use in the treatment of acne, acne rosacea and seborrhoea.

## 5 PRIOR ART

A very large number of people suffer from acne which has a pathological cutaneous picture characterised by a morphological and functional alteration of the pilosebaceous organ with appearance of whiteheads (closed comedo), blackheads (open comedo), papules and in the more serious forms, pustules, nodules, cysts and  
10 scars.

Acne affects about 80% of the population between the ages of 12 and 30 and, above all in women, may persist even to a more advanced age.

The etiopathogenesis of acne is in close relationship with:

- an increase in the production of sebum (seborrhoea)
- 15 • an anomalous keratinisation of the pilosebaceous duct
- a bacterial colonization

Seborrhoea is a consequence of an exasperated reaction of the sebaceous gland to the action of androgen hormones, to be more exact the action of dihydrotestosterone caused by the reduction of testosterone caused by the enzyme 5 -  
20  $\alpha$  reductase.

Anomalous keratinisation of the pilosebaceous duct is the direct cause of formation of a keratic plug, cause of formation of microcomedo and later of acne lesions. Due to the increase in production of sebum, and prior to the formation of microcomedo, there is an anomalous growth of cutaneous saprophyte bacteria, such  
25 as *Propionibacterium Acnes*. The latter, due to the release of lytic enzymes (protease and lipase), capable of destroying the protein structure of the sebaceous gland and to hydrolyse the triglycerides normally contained in the sebum (which besides is produced in larger quantities due to the action of dihydrotestosterone) releasing fatty acids and glycerol. The fatty acids released in this way are characterised by their

comedogenic action and are therefore oxidised, forming chemical compounds favouring inflammation.

The therapy used up to now in the pharmaceutical treatment of acne or cosmetic treatment of the seborrhea has been mainly based on the action of  
5 keratolytic and/or anti-biotic substances, or other active principles, for example, retinoids

Among these substances may be mentioned for example salycilic acid, tartaric acid, glycolic acid, resorcin, phenol etc., all capable of carrying out their action aimed at clinically improving the acneic picture through a keratolytic type mechanism.

10 Among the antibiotic substances used up until now to keep the increase of *Propionibacterium Acnes* under control worthy of mention are clindamycine, minocycline, erythromycin, metronidazole, etc.

Other active principles used in treating acne are trans-retinoic acid, found to be efficacious, but characterised by being highly toxic, photo-toxic and teratogenic.

## 15 OBJECT AND SUMMARY OF THE INVENTION

The object of the invention is to provide a new product characterised by being highly efficacious with excellent cutaneous tolerability, in particular in the treatment of seborrhoea, acne and acne rosacea.

The object is achieved, according to the invention, with a composition, which  
20 is characterised by the fact that it contains as an active ingredient a mixture including the ethyl ester of linoleic acid (ethylinoleate) and triethylester of citric acid (triethylcitrate).

This composition results as being able, among other things, to inhibit the activity of specific enzymes, such as for example, 5-alpha reductase, lipase and  
25 esterase, enabling a control of the seborrhoea and in general the evolution of the acneic and rosacea picture.

## DETAILED DESCRIPTION OF THE INVENTION

According to this invention, ethyllinoleate and triethylcitrate can be contained in a composition each in a quantity in weight from between 0.1 to 99.9%, preferably  
30 in equal quantities from between 1.00 and 40% each, based on the final weight of the composition.

Furthermore, the composition based on ethyllinoleate and triethylcitrate can also contain various active ingredients, which for descriptive simplicity will be defined as *synergists*.

The synergists can be chosen from between acetic acid, lactic acid, salicylic acid, tartaric acid, glycolic acid, clindamycin, erythromycin, metronidazole, amoxicillin, triclosan, capryloyl glycine, azelaic acid, zinc hydroxide, zinc chloride, trans-retinoic acid, resorcinol, hyaluronic acid, gentamicin, meclocycline, phenol, ascorbic acid, tocopherol, lipoic acid, phosphatidylcholine, phosphatidylserine, chlorhexidine, irgasan, adapalene, phospholipids in general, in all the dextrorotary, levorotary forms, racemic mixtures, cis forms, trans forms and relative salts, esters and amides and formulated together with particular additives and excipients for external use.

These synergists may be present in the composition, individually or combined, in two or more, together with ethyllinoleate and triethylcitrate.

These synergists may be contained in variable weight quantities from between 0.001 to 70%, preferably from 0.5 to 15% based on the final formulation when the proportions of ethyllinoleate and triethylcitrate are each from between 0.5 to 90.5% in weight.

The clinical efficacy and safety of use are the consequence of an original mechanism of action characterised by the fact that both ethyllinoleate and triethylcitrate, which in themselves behave as inert substances, are transformed into active principles once in contact with the skin. This transformation, from an inert substance into an active principle is a result of the hydrolysis, which takes place through specific cutaneous enzymes or bacteria (lipase and esterase) capable of releasing ethyl alcohol and respectively linolenic acid, diethyl citrate then monoethyl citrate and finally citric acid.

The action mechanism of the composition of the invention can be described more in detail as follows.

Ethyllinoleate and triethylcitrate synergically are able to reduce seborrhoea and hyper keratinisation of the pilosebaceous duct; this action is achieved through the release of the respective acid forms, through hydrolysis of the esters by the action of the lipase bacteria.

In this invention it has been proven that hydrolysis of ethyllinoleate and triethylcitrate carried out by lipase bacteria is to be preferred to hydrolysis of the triglycerides (lipid component of sebum) carried out by the same lipase bacteria, consequently avoiding an irritative condition due to the release of fatty acids achieved through hydrolysis of the triglycerides.

In relation to hyper keratinisation of the pilosebaceous duct, the combined action of ethyllinoleate and triethylcitrate is innovative in that the former prevents hyper-keratinisation whereas the latter cures it, behaving as a keratolytic. This combined action results in higher efficacy compared with the effect of the two components taken individually.

In relation to seborrhoea the combined action of ethyllinoleate and triethylcitrate is innovative in that it results in a decrease in the sebum levels achieved by inhibiting the 5-alpha reductase enzyme, an enzyme which as stated above is the cause of the reduction of testosterone to dihydrotestosterone whose action is capable of increasing the production of sebum. Once ethyllinoleate is hydrolysed into linoleic acid, it is able to inhibit the activity of 5-alpha reductase by a direct mechanism, whereas triethylcitrate, once hydrolysed into citric acid, acts in an indirect way, creating an environment where the activity of the aforementioned enzyme is obstructed.

In other words, lipase bacteria recognise the ethyllinoleate and triethylcitrate mixture as the preferential substratum rather than the triglycerides of the sebum and so do not interfere with the structure of these triglycerides, thus reducing the inflammatory pathologies of seborrhoea and acne.

EFFECTS OF THE INVENTION IN RELATION TO TESTS RESERVED ON SAMPLES.

Based on the present invention, tests were carried out to evaluate experimentally the action of two products, a lotion and a cream, for the treatment of acne through a clinical test using a sebumetric measuring device.

#### Aim

The test is able to evaluate if the products being tested are a valid help in the treatment against acne and if they are able to mitigate reddening due to the presence of acne focus.

**Test specimen**

Five female volunteers from between 15 and 28 years of age with greasy skin and suffering from acne.

**Preparation of samples**

- 5           The samples must be applied, on the basis of their use characteristics, as they are.

**Method of application of samples**

The samples must be applied uniformly on specific parts of the face, according to the indications given on the description card handed to the volunteer.

- 10           The lotion on the right side of the face; the cream on the left side of the face.

**Carrying out the test**

After finding the volunteers for the test, the following instrumental evaluations are carried out:

- 15           ➤ basic sebum measurement using an authorized sebumetric device in compliance with EEC regulations (SKIN LAB®)
- Basic hydration using an authorized instrument in compliance with EEC regulations (SKIN LAB®)
- Basic TEWL using an authorized instrument in compliance with EEC regulations (Tewameter®) – only on the left side of the face
- 20           ➤ Acquisition of micro photographs using a video camera with polarised light – VIDEOCAP – with 20x enlargements and, when possible, 200x. The micro images are necessary to visualise in depth the slight blemishes due to acne and to highlight any improvements during the treatment under examination.
- Acquisition of macro photographs with Mini DV. The photographs are useful
- 25           in defining the general start situation and to document any macroscopic improvements during the use of the products.

Furthermore the volunteers are supplied with a card on which to register daily observations about the cosmetic agreeable nature of the products and their performance.

- 30           Each volunteer is given a card describing how she must apply the various products being tested. To facilitate the task, the first application is carried out on the premises.

The following controls are carried out after seven days (t7), fourteen days (t14), twenty one days (t21) and twenty eight days (t28) of treatment with a lotion and a cream.


5      Following the above experiment, the difference between the sebumetric, keratic and TEWL values measured before and after the application of the products using the polarised light video camera and with the Mini DV the variations of the furuncles and acne pustules was evaluated.

The sebumetric, keratic and TEWL values are registered, elaborated and graphically presented together with the results in the following tables.


## TABLES AND GRAPHIC REPRESENTATION OF THE RESULTS

## Sebometric values after prolonged use

## LOTION




## % Decrease in sebum on the skin







## Hydration indexes after prolonged use




## Sebometric values after prolonged use



## Hydration indexes after prolonged use



## TEWL values after prolonged use



**EXAMPLES of FORMULATION**

Here following are some examples of formulations according to the present invention.

5

**Preparation 01 – oleolita**

N°	Description	% w/w
01	Ethyllinoleate	20.00
02	Triethylcitrate	80.00

10 Method of preparation: mix 01 in 02

**Preparation 02 – alcoholic solution**

N°	Description	%w/w
01	Ethyllinoleate	20.00
02	triethylcitrate	20.00
03	salicylic acid	2.00
04	ethyl acid	58.00

15

Method of preparation: dissolve 03 in 04; to the solution mix 01 + 02

20 **Preparation 03 – emulsion**

N °	Description	%w/w
-----	-------------	------

**PHASE A**

01	Ethyllinoleate	5.00
02	triethylcitrate	5.00
03	Ascorbil palmitate	1.50
04	Ppg – 15 stearyl ether	10.00
05	Capryloyl glycine	4.00
06	Steareth –2	3.00
07	Steareth – 21	2.00

25

30 **PHASE B**

08	Preservatives	as req.
09	Glycerol	3.00
10	Water	as req.

Method of preparation: Phase A, mix 01 + 02 + 03 + 04 + 05 + 06 + 07 and heat to 75°C; Phase B, mix 08 + 09 + 10 and heat the pre-mix to + 75°C, then add under agitation the Phase B to Phase A. Cool to room temperature always agitating.

5 **Preparation 04 – Alcoholic solution**

	N°	Description	%w/w
	01	Ethyllinoleate	20.00
	02	Triethylcitrate	20.00
	03	Erythromycin	10.00
10	04	ethyl acid	50.00

Method of preparation: dissolve 03 in 04, mix 01 + 02 in the solution

**Preparation 05 – Alcoholic solution**

	N°	Description	%w/w
15	01	Trans-retinoic	0.025
	02	ethyllinoleate	5.00
	03	triethylcitrate	20.00
	04	ethylic acid	as req.

Method of preparation: dissolve 01 + 02 + 03 + in 04

20

**Preparation 06 - Alcoholic solution**

	N°	Description	%w/w
	01	clindamycin	1.00
	02	ethyllinoleate	5.00
25	03	triethylcitrate	20.00
	04	ethyl acid	as.req.

Method of preparation: mix 02 + 03 + 04 then dissolve 01 in it.

30 It has therefore been proved that the action of ethyllinoleate and triethylcitrate, described in the treatment of acne, greasy skin and seborrhoea, in consideration of the particular biological, pharmacological, physiological and biochemical action mechanism, has been found to be wider and is addressed to the treatment of several other cutaneous pathologies such as for example atopic

dermatitis, dermatitis seborrheica, exfoliative dermatitis, stasis dermatitis, neurodermatitis, acne, acne rosacea, alopecia areata, scarring alopecia, female alopecia, anagen effluvium, Hippocratic alopecia, psoriasis, Lichen, ichthyosis, xerodermia, keratosis pilaris, decubital ulcer, trophic ulcer, torpid sores, angioma  
5 nevus or vascular bundle, hemangioma, granuloma telangiectaticum, keratosis seborrhoea, etc.

The use of ethyllinoleate and triethylcitrate, also combined with opportune synergists, due to its particular action mechanism on the skin is innovative even as regards to its cosmetic use, such as: anti-aging composition aimed at improving the  
10 aesthetic conditions of the skin and to prevent signs of cutaneous aging; anti-wrinkle; moisturiser; the treatment of cutaneous hyper-pigmentation; cosmetic treatment of seborrhoea with tendency to develop into acne.

"COMPOSITION BASED ON ETYLLINOLEATE AND TRIETHYLCITRATE  
FOR THE TREATMENT OF SEBORRHEA AND ACNE"

\* \* \* \* \*

CLAIMS

1. Composition for topical use for treating and improving the aesthetic conditions of the skin comprising, as an active ingredient, a mixture of ethyllinoleate  
5 and triethylcitrate.

2. Composition for topical use according to claim 1, characterised in that the ethyllinoleate is contained in a quantity from 0.1 to 99% weight/weight and the triethylcitrate in a quantity from 99% to 0.1% weight / weight.

3. Composition for topical use according to claims 1 and 2, which contains in  
10 addition active ingredients, used singularly or in combination, such as acetic acid, lactic acid, salicylic acid, tartaric acid, glycolic acid, clindamycin, minocycline, erythromycin, metronidazole, amoxycillin, triclosan, capryloyl glycine, azelaic acid, zinc hydroxide, zinc chloride, vitamin A trans-retinoic acid, resorcinol, hyaluronic acid, gentamicin, meclocycline, phenol, ascorbic acid, tocopherol, lipoic acid,  
15 phosphatidylcholine, phosphatidylserine, chlorhexidine, irgasan, adapalene, phospholipids in general, in all the dextrorotary, levorotary forms, racemic mixtures, cis forms, trans forms and relative salts, esters and amides and formulated in a base of particular additives and excipients for external use.

4. Composition for topical use according to claim 3, wherein the active added  
20 ingredients are contained in a quantity from 0,001 to 90% weight/weight, preferably from 0.5 to 15% weight/weight.

5. Composition for topical use according to claims 1 and 2, which is prepared in formulations for external use, such as water emulsions in oil, oil emulsions in water, mono-phase solutions, dual-phase pseudo-solutions, mono-phase gels, dual-phase gels  
25 or sub-micelle gels, anhydrous ointments, powder sprinklers, alcoholates, alcohol solutions, hydro-alcoholic solutions.

6. Use of composition according to claims 1 and 2 for the treatment of seborrhoea, acne and acne rosacea.

7. A method for the treatment of the skin, in particular for the treatment of  
30 seborrhoea, acne and acne rosacea comprising the steps of using a composition



containing a mixture of ethyllinoleate and triethylcitrate and applying the composition locally on the parts of the skin affected by seborrhoea, acne and acne rosacea, for a period of time and in quantities sufficient for a preservation of the structural integrity of the triglycerides of the sebum, whereby the composition provide  
5 a preferential substratum for the action of the lipase bacteria or the cutaneous esterase so as to decrease the pre-digestion of triglycerides on the part of lipase bacteria and cutaneous esterase.

8. The method of claim 7, according to which the composition containing the ethyllinoleate and triethylcitrate mixture is applied on the skin for a transformation of  
10 the ethyllinoleate and triethylcitrate into their respective acid forms by means of lipase bacteria or cutaneous esterase so as to form an active component able to act directly and indirectly against the causes of seborrhoea , acne and acne rosacea.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 02/00791

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P17/08 A61P17/10 A61K31/23 A61K31/225 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ, WPI Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	EP 1 269 991 A (G.DE PAOLI AMBROSI) 2 January 2003 (2003-01-02) claims 1-9 page 2, line 5-7 ---	1-8
A	WO 99 29335 A (CHONG KUN DANG) 17 June 1999 (1999-06-17) claims 1,6,9,14 example 4 ---	1,2,4
A	WO 99 00002 A (CHONG KUN DANG) 7 January 1999 (1999-01-07) claims 1,3,5,8,13 example 5 ---	1,2,4
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

10 March 2003

Date of mailing of the international search report

26/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 02/00791

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 24 52 119 A (HENKEL) 13 May 1976 (1976-05-13) claim 1 page 3, paragraph 1 examples 1-4 ---	1,2,4-6
A	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 111:239549, 1989 Y.TOYONO E.A.: "Prophylactic antiacne agents containing linoleic acid derivatives" Database accession no. 1989:639549 XP002234115 abstract -----	1,2,4-6
A	& JP 01 110610 A (LION) 27 April 1989 (1989-04-27) -----	1,2,4-6

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IT 02/00791

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claims 7 and 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 02/00791

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1269991	A	02-01-2003	EP 1269991 A2	02-01-2003
WO 9929335	A	17-06-1999	AU 1509799 A WO 9929335 A1	28-06-1999 17-06-1999
WO 9900002	A	07-01-1999	AU 9465898 A BR 9815350 A CA 2313015 A1 CN 1280502 T EP 1035862 A2 HU 0004379 A2 JP 2001517602 T WO 9900002 A2 NO 20002800 A NZ 504844 A US 6028067 A US 6063762 A ZA 9810885 A	19-01-1999 16-10-2001 07-01-1999 17-01-2001 20-09-2000 28-08-2001 09-10-2001 07-01-1999 03-08-2000 30-11-2001 22-02-2000 16-05-2000 27-05-1999
DE 2452119	A	13-05-1976	DE 2452119 A1	13-05-1976
JP 1110610	A	27-04-1989	NONE	